NEW YORK (TheStreet) -- Horizon Pharma (HZNP) - Get Report stock is up by 12.11% to $19.35 in mid-morning trading on Friday, after the company's 2015 third quarter results beat expectations.

Before the market open today, the Dublin-based biotechnology company reported adjusted earnings of 70 cents per share, compared to earnings of 19 cents per share for the year-ago period.

Revenue increased by 202% year over year to $226.5 million. 

Analysts surveyed by Zacks Investment Research projected that the company would report earnings of 41 cents per share on revenue of $192 million. 

"Our business fundamentals have never been better, we significantly exceeded expectations on net sales, adjusted EBITDA and adjusted diluted earnings per share and our cash flow generation continues to be very strong," Horizon Pharma CEO Timothy Walbert said in a statement.

Separately, TheStreet Ratings team rates HORIZON PHARMA PLC as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:

We rate HORIZON PHARMA PLC (HZNP) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its disappointing return on equity.

You can view the full analysis from the report here: HZNP

Image placeholder title

HZNP

data by

YCharts

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.